Caroline Seymour

In both the KEYNOTE-641 and KEYNOTE-789 trials, pembrolizumab, in addition to standard therapies, did not improve survival outcomes in their target populations.

Atezolizumab did not yield a significant improvement in overall survival compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.

In an 8 to 5 vote, ODAC voted in support of launching 2 single-arm trials seeking to characterize the risk-benefit profile of dostarlimab for patients with dMMR/MSI-H locally advanced rectal cancer.

A combined regimen of mitazalimab and mFOLFIRINOX resulted in a 52% objective response rate among 23 patients with metastatic pancreatic cancer.

In the PEARL trial, monotherapy with durvalumab did not deliver a statistically significant improvement in overall survival vs platinum-based chemotherapy as frontline treatment in patients with PD-L1-high stage IV non–small cell lung cancer.

After 13.1 months of follow-up, the median progression-free survival in patients with EGFR-mutant non–small cell lung cancer who received a sintilimab-based regimen was 5.5 months.

A presentation at the 2022 ESMO Congress found that xevinapant plus chemoradiotherapy decreased the risk of death by twice that of placebo for patients with unresectable, locally advanced head and neck squamous cell carcinoma.

An analysis of patient-reported outcomes showed that patients with advanced ovarian cancer experienced fewer abdominal or gastrointestinal toxicities with mirvetuximab soravtansine than with chemotherapy.

Phase 2 findings indicate that a combination of avelumab and axitinib may draw promising responses in patients with advanced type B3 thymoma and thymic carcinoma.

A subgroup of the phase 3 GLOW trial revealed a unique relationship between undetectable minimal residual disease status and progression-free survival in elderly or unfit patients with chronic lymphocytic leukemia who received ibrutinib plus venetoclax.

Tivozanib, an oral VEGF inhibitor, improved overall survival in patients with relapsed or refractory, advanced renal cell carcinoma.

At a median follow-up of 22.9 months, patients with platinum-refractory metastatic urothelial carcinoma achieved a median overall survival of 14.6 months with EphB4-human serum albumin plus pembrolizumab.

Rucaparib may be a viable maintenance therapy option for patients with DNA repair–deficient positive, metastatic urothelial cancer who are unlikely to benefit from avelumab immunotherapy.

Phase 1 findings showed a 50% overall response rate among patients with EGFR-mutated non–small cell lung cancer who received amivantamab in combination with lazertinib plus carboplatin and pemetrexed.

A biologics license application for the IL-15 superagonist N-803 has been accepted and the agent will be reviewed for the treatment of patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer carcinoma in situ.

Mosunetuzumab, a CD20 and CD3 T-cell engaging bispecific antibody, received a priority review designation from the FDA for the treatment of patients with relapsed/refractory follicular lymphoma following at least 2 prior systemic therapies.

Mirvetuximab soravtansine (IMGN853) has been granted priority review by the FDA for the treatment of patients with FRα-high, platinum-resistant ovarian cancer who have previously received between 1 and 3 systemic therapies.

Phase 3 findings from the AEGEAN trial demonstrated that adding durvalumab to platinum-based chemotherapy regimens improved pathologic complete response and major pathologic response among patients with resectable non–small cell lung cancer.

A subgroup analysis found that the addition of durvalumab to chemotherapy resulted in maintained overall survival benefit in patients with advanced biliary tract cancer, regardless of primary tumor location.

Patients with multiple myeloma who received initial combination therapy with lenalidomide, bortezomib, and dexamethasone, plus autologous stem cell transplant, followed by lenalidomide maintenance, experienced improved progression-free survival.

Standard chemotherapy plus sorafenib achieved clinical benefit in pediatric patients with FLT3-ITD–positive acute myeloid leukemia.

An improved progression-free survival benefit was observed in patients with stage III unresectable or stage IV melanoma who received nivolumab plus ipilimumab.

Whether administered as an immune primer or concurrently with extended field chemoradiation, atezolizumab demonstrated efficacy in triggering T-cell clonal expansions and prolonging progression-free survival in patients with cervical cancer.

Duvelisib, a dual PI3K-δ,γ inhibitor, is now listed as a category 2A designated option for second-line and subsequent treatment of patients with relapsed/refractory peripheral T-cell lymphoma in the National Comprehensive Cancer Network Clinical Practice Guidelines.

Frontline niraparib, abiraterone acetate, and prednisone yielded improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.

A City of Hope expert underscores the benefit of using antibody-drug conjugates, CDK4/6 inhibitors, PARP inhibitors, and checkpoint blockade in early-stage and metastatic breast cancer.

Pending FDA approval, the dual immunotherapy combination could provide patients with a new treatment option which would not require any further safety requirements prior to initiation.

Patients who received matched targeted therapy specific to their genomic alteration, as identified through multigene sequencing, experienced significantly improved progression-free survival.

A study in France showed that patients with lung cancer, a population initially excluded from COVID-19 vaccination registration trials, were able to safely receive 3 doses.

Findings from biomarker tests for patients with chronic lymphocytic leukemia can help appropriately tailor therapy plans as well as identify patients eligible for clinical trials.